Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer

Allarity Therapeutics, Inc.

Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.
Two patients in ongoing phase 2 remain on stenoparib for over 17 months without progression.
Protocol incorporates FDA feedback and IRB approval; critical data expected by end of summer 2026 for pivotal trial.
Trial will evaluate stenoparib-DRP companion diagnostic alongside drug for dual regulatory submission.
Targets $9B+ PARP inhibitor market and addresses FDA Project Optimus dose-finding guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.